These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 29259521)

  • 1. Nuclease-Mediated Gene Therapies for Inherited Metabolic Diseases of the Liver.
    Bryson TE; Anglin CM; Bridges PH; Cottle RN
    Yale J Biol Med; 2017 Dec; 90(4):553-566. PubMed ID: 29259521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Curative Ex Vivo Hepatocyte-Directed Gene Editing in a Mouse Model of Hereditary Tyrosinemia Type 1.
    VanLith C; Guthman R; Nicolas CT; Allen K; Du Z; Joo DJ; Nyberg SL; Lillegard JB; Hickey RD
    Hum Gene Ther; 2018 Nov; 29(11):1315-1326. PubMed ID: 29764210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic-Based Approaches to Inherited Metabolic Liver Diseases.
    Zabaleta N; Hommel M; Salas D; Gonzalez-Aseguinolaza G
    Hum Gene Ther; 2019 Oct; 30(10):1190-1203. PubMed ID: 31347416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liver targeted gene therapy: Insights into emerging therapies.
    Moscoso CG; Steer CJ
    Drug Discov Today Technol; 2019 Dec; 34():9-19. PubMed ID: 33357766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene Therapy in Tyrosinemia: Potential and Pitfalls.
    Carter S; Doyon Y
    Adv Exp Med Biol; 2017; 959():231-243. PubMed ID: 28755200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current Status on Clinical Development of Adeno-Associated Virus-Mediated Liver-Directed Gene Therapy for Inborn Errors of Metabolism.
    Ginocchio VM; Ferla R; Auricchio A; Brunetti-Pierri N
    Hum Gene Ther; 2019 Oct; 30(10):1204-1210. PubMed ID: 31517544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In Vivo AAV-CRISPR/Cas9-Mediated Gene Editing Ameliorates Atherosclerosis in Familial Hypercholesterolemia.
    Zhao H; Li Y; He L; Pu W; Yu W; Li Y; Wu YT; Xu C; Wei Y; Ding Q; Song BL; Huang H; Zhou B
    Circulation; 2020 Jan; 141(1):67-79. PubMed ID: 31779484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cas9-nickase-mediated genome editing corrects hereditary tyrosinemia in rats.
    Shao Y; Wang L; Guo N; Wang S; Yang L; Li Y; Wang M; Yin S; Han H; Zeng L; Zhang L; Hui L; Ding Q; Zhang J; Geng H; Liu M; Li D
    J Biol Chem; 2018 May; 293(18):6883-6892. PubMed ID: 29507093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genome editing for inborn errors of metabolism: advancing towards the clinic.
    Schneller JL; Lee CM; Bao G; Venditti CP
    BMC Med; 2017 Feb; 15(1):43. PubMed ID: 28238287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What´s new in Gene Therapy of Hemophilia.
    Rodriguez-Merchan EC
    Curr Gene Ther; 2018; 18(2):107-114. PubMed ID: 29446741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cell transplantation in liver-directed gene therapy.
    Raper SE; Wilson JM
    Cell Transplant; 1993; 2(5):381-400; discussion 407-10. PubMed ID: 8162279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CRISPR/Cas9 therapeutics for liver diseases.
    Aravalli RN; Steer CJ
    J Cell Biochem; 2018 Jun; 119(6):4265-4278. PubMed ID: 29266637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CRISPR/Cas9-mediated genome editing via postnatal administration of AAV vector cures haemophilia B mice.
    Ohmori T; Nagao Y; Mizukami H; Sakata A; Muramatsu SI; Ozawa K; Tominaga SI; Hanazono Y; Nishimura S; Nureki O; Sakata Y
    Sci Rep; 2017 Jun; 7(1):4159. PubMed ID: 28646206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel vectors and approaches for gene therapy in liver diseases.
    Maestro S; Weber ND; Zabaleta N; Aldabe R; Gonzalez-Aseguinolaza G
    JHEP Rep; 2021 Aug; 3(4):100300. PubMed ID: 34159305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice.
    Yang Y; Wang L; Bell P; McMenamin D; He Z; White J; Yu H; Xu C; Morizono H; Musunuru K; Batshaw ML; Wilson JM
    Nat Biotechnol; 2016 Mar; 34(3):334-8. PubMed ID: 26829317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver directed adeno-associated viral vectors to treat metabolic disease.
    Chuecos MA; Lagor WR
    J Inherit Metab Dis; 2024 Jan; 47(1):22-40. PubMed ID: 37254440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Advances in gene therapy for β-thalassemia and hemophilia based on the CRISPR/Cas9 technology].
    Bao LW; Zhou YY; Zeng FY
    Yi Chuan; 2020 Oct; 42(10):949-964. PubMed ID: 33229321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coupling AAV-mediated promoterless gene targeting to SaCas9 nuclease to efficiently correct liver metabolic diseases.
    De Caneva A; Porro F; Bortolussi G; Sola R; Lisjak M; Barzel A; Giacca M; Kay MA; Vlahoviček K; Zentilin L; Muro AF
    JCI Insight; 2019 Jun; 5(15):. PubMed ID: 31211694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delivery methods for site-specific nucleases: Achieving the full potential of therapeutic gene editing.
    Liu J; Shui SL
    J Control Release; 2016 Dec; 244(Pt A):83-97. PubMed ID: 27865852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CRISPR/Cas9-Mediated Gene Correction in Newborn Rabbits with Hereditary Tyrosinemia Type I.
    Li N; Gou S; Wang J; Zhang Q; Huang X; Xie J; Li L; Jin Q; Ouyang Z; Chen F; Ge W; Shi H; Liang Y; Zhuang Z; Zhao X; Lian M; Ye Y; Quan L; Wu H; Lai L; Wang K
    Mol Ther; 2021 Mar; 29(3):1001-1015. PubMed ID: 33221434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.